TrialJournal of neurodevelopmental disorders2022

A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX).

Elizabeth Berry-Kravis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.